Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - tamoxifen citrate - oral tablet - 20mg

Estats Units - anglès - NLM (National Library of Medicine)

bryant ranch prepack - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole tablets. if anastrozole is used during pregnancy, or if the patient becomes pregnant

Estats Units - anglès - NLM (National Library of Medicine)

a-s medication solutions - anastrozole (unii: 2z07myw1az) (anastrozole - unii:2z07myw1az) - anastrozole 1 mg - anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. anastrozole tablets are indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. anastrozole tablets are indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. patients with er-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets. anastrozole tablets may cause fetal harm when administered to a pregnant woman and offers no clinical benefit to premenopausal women with breast cancer. anastrozole tablets are contraindicated in women who are or may become pregnant. there are no adequate and well-controlled studies in pregnant women using anastrozole tablets. if anastrozole is used during pregnancy, or if the patient becomes pregnant

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

tillomed laboratories ltd - tamoxifen citrate - oral tablet - 20mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - tamoxifen citrate - oral tablet - 20mg

Malàisia - anglès - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - tamoxifen citrate -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

ad management services pty ltd t/a the natural way - aesculus hippocastanum,allium sativum,dl-alpha tocopheryl acetate,ginkgo biloba,rutin -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

natural bio pty limited - allium sativum,althaea officinalis,armoracia rusticana,ascorbic acid,trigonella foenum-graecum -